Skip to main content

Medistim ASA (0OCD.L)

London Stock Exchange Healthcare Medical - Equipment & ServicesView data quality →
58.3Fair

ValueMarkers Composite Index

Top 73%#12,250 of 44,707
Undervalued

79% below intrinsic value ($12)

UndervaluedFair ValueOvervalued
Piotroski
7/9
Strong
Beneish
-2.67
Low Risk
Altman
15.32
Safe
DCF Value
$12
Overvalued
ROIC
29.2%
Strong
P/E
26.5
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Medistim ASA (0OCD.L) — VMCI valuation read

0OCD.L screens at VMCI 58/100, a 8-point gap above the Healthcare sector median (50). For a mid-cap Medistim ASA share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.

0OCD.L has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: 0OCD.L trades at 20.0x earnings, 11% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 2.0x is the rate-sensitivity line to watch, which sets the rate-cycle exposure for Medistim ASA.

0OCD.L rose 3.2% over the trailing 7 days, with a -17.8% read on a 30-day basis.

Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.

CEO: Kari Eian Krogstad154 employeesNOwww.medistim.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 0OCD.L’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.